Literature DB >> 14747615

Alterations in vesicular dopamine uptake contribute to tolerance to the neurotoxic effects of methamphetamine.

Kamisha L Johnson-Davis1, Jannine G Truong, Annette E Fleckenstein, Diana G Wilkins.   

Abstract

Previous studies demonstrated that tolerance to the long-term neurotoxic effects of methamphetamine on dopamine neurons could be induced by pretreating with multiple injections of escalating doses of methamphetamine. The mechanism(s) underlying this tolerance phenomenon is unknown. Some recent studies suggested that aberrant vesicular monoamine transporter-2 (VMAT-2) and dopamine transporter function contribute to neurotoxic effects of methamphetamine. Hence, the purpose of this study was to explore the role of the VMAT-2 and dopamine transporter in the induction of tolerance to the longterm persistent dopaminergic deficits caused by methamphetamine. A second purpose was to investigate the potential role of hyperthermia and alterations in brain methamphetamine distribution in this tolerance. Results revealed that the methamphetamine pretreatment regimen attenuated both the acute methamphetamine-induced decrease in VMAT-2 function 2 h after the methamphetamine challenge administration and its resulting persistent dopamine deficits without attenuating the acute methamphetamine-induced decreases in dopamine transporter uptake. Furthermore, pretreatment with methamphetamine prior to a high-dose methamphetamine challenge administration also attenuated the acute methamphetamine-induced redistribution of VMAT-2 immunoreactivity within the nerve terminal. This protection was not due to alterations in concentration of methamphetamine in the brain because both the methamphetamine- and saline-pretreated rats had similar amounts of methamphetamine and amphetamine at 30 min to 2 h after the last methamphetamine challenge injection. In summary, these data are the first to demonstrate an association between the prevention of acute alterations in vesicular dopamine uptake and the development of tolerance to the neurotoxic effects of methamphetamine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14747615     DOI: 10.1124/jpet.103.062695

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  17 in total

Review 1.  Preconditioning provides neuroprotection in models of CNS disease: paradigms and clinical significance.

Authors:  R Anne Stetler; Rehana K Leak; Yu Gan; Peiying Li; Feng Zhang; Xiaoming Hu; Zheng Jing; Jun Chen; Michael J Zigmond; Yanqin Gao
Journal:  Prog Neurobiol       Date:  2014-01-02       Impact factor: 11.685

2.  Prior methamphetamine self-administration attenuates the dopaminergic deficits caused by a subsequent methamphetamine exposure.

Authors:  Lisa M McFadden; Paula L Vieira-Brock; Glen R Hanson; Annette E Fleckenstein
Journal:  Neuropharmacology       Date:  2015-01-31       Impact factor: 5.250

3.  Alterations in the striatal dopamine system during intravenous methamphetamine exposure: effects of contingent and noncontingent administration.

Authors:  Goran Laćan; Martin Hadamitzky; Ronald Kuczenski; William P Melega
Journal:  Synapse       Date:  2013-03-19       Impact factor: 2.562

4.  Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure.

Authors:  Lisa M McFadden; Greg C Hadlock; Scott C Allen; Paula L Vieira-Brock; Kristen A Stout; Jonathan D Ellis; Amanda J Hoonakker; David M Andrenyak; Shannon M Nielsen; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2011-10-27       Impact factor: 4.030

5.  Methamphetamine self-administration acutely decreases monoaminergic transporter function.

Authors:  Lisa M McFadden; Kristen A Stout; Paula L Vieira-Brock; Scott C Allen; Shannon M Nielsen; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  Synapse       Date:  2011-12-13       Impact factor: 2.562

6.  Methamphetamine treatment during development attenuates the dopaminergic deficits caused by subsequent high-dose methamphetamine administration.

Authors:  Lisa M McFadden; Amanda J Hoonakker; Paula L Vieira-Brock; Kristen A Stout; Nicole M Sawada; Jonathan D Ellis; Scott C Allen; Elliot T Walters; Shannon M Nielsen; James W Gibb; Mario E Alburges; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  Synapse       Date:  2011-03-21       Impact factor: 2.562

7.  Methamphetamine preconditioning: differential protective effects on monoaminergic systems in the rat brain.

Authors:  Jean Lud Cadet; Irina N Krasnova; Bruce Ladenheim; Ning-Sheng Cai; Michael T McCoy; Fidelis E Atianjoh
Journal:  Neurotox Res       Date:  2009-02-24       Impact factor: 3.911

8.  Methamphetamine-induced dopaminergic deficits and refractoriness to subsequent treatment.

Authors:  Jarom E Hanson; Elisabeth Birdsall; Kristi S Seferian; Marcus A Crosby; Kristen A Keefe; James W Gibb; Glen R Hanson; Annette E Fleckenstein
Journal:  Eur J Pharmacol       Date:  2009-04-01       Impact factor: 4.432

Review 9.  VMAT2 gene expression and function as it applies to imaging beta-cell mass.

Authors:  Paul E Harris; Caterina Ferrara; Pasquale Barba; Teresa Polito; Matthew Freeby; Antonella Maffei
Journal:  J Mol Med (Berl)       Date:  2007-07-31       Impact factor: 4.599

10.  Methamphetamine preconditioning alters midbrain transcriptional responses to methamphetamine-induced injury in the rat striatum.

Authors:  Jean Lud Cadet; Michael T McCoy; Ning Sheng Cai; Irina N Krasnova; Bruce Ladenheim; Genevieve Beauvais; Natascha Wilson; William Wood; Kevin G Becker; Amber B Hodges
Journal:  PLoS One       Date:  2009-11-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.